ABSTRACT

Targeted therapies as an alternative to conventional cytotoxic therapies leads to a new approach to cancer therapy in the last decade. Seven new drugs were approved in treatment of metastatic renal cell carcinoma in such a short period of seven years. Initial utilization of the targeted therapies was encoureged to improve the survival and well being of the patients with locally advanced and metastatic renal cell carcinoma. The new subject of research on these drugs which are shown to be superior to immunotherapy and conventional chemotherapy, is how to integrate them to surgery at early stage disease and how to utilize them before surgery at locally advanced disease. This research of field is going to be popular in the near future, although we have limited experience and knowledge about this subject at the moment.